

Index

Page numbers in *italics* refer to illustrations; those in **bold** refer to tables

- AARS mutations 224
ABCD1 mutations 310
aceruloplasminemia 317, 318–319
 diagnosis 319
 investigations 318–319
 pathophysiology 318
 spectrum of clinical phenotype 318
 treatment options 319
acid sphingomyelinase deficiencies 303–304
adaptor proteins (AP) 172
Addison's disease 309
 treatment 314
adolescent cerebral adrenoleukodystrophy 309
adrenomyeloneuropathy (AMN) 309
 neuropathology 310
adult cerebral adrenoleukodystrophy 309
aging 1
 excitotoxicity involvement 40
agitation management in dementia 112
alanyl t-RNA synthetase (AARS) mutations 224
alien limb phenomenon, corticobasal
 degeneration 94
alpha-synuclein (α -SN) 4, 4, 13
 dementia with Lewy bodies 85, 86
 filaments 16–17
 Lewy bodies 16–17
 morphological differences 19
 synthetic 17
 multiple system atrophy 61–62, 61, 62
 Parkinson disease 46
 prion-like mechanism of spread 49–50
 SNCA gene mutations 12, 13
 therapeutic approaches 19–20
 transfer between cells 49
 see also synucleinopathies; synucleins
ALSIN mutation 142
Alzheimer's disease (AD) 102
 atypical phenotype 104
 biomarkers 87, **103**
 dementia phase 103, **103**
 diagnosis 107–110, 244
 examination 109
 guidelines 2
 history 107–109
 investigation 109–111
 disease progression 244
 environmental factors 107
 epidemiology 102
 excitotoxicity 39, 41
 future developments 112
 genetics 6–8, 106–107
 early-onset familial AD 41, 106
 late-onset AD 107
 historical background 102
 management 110–112
 agitation management 112
 medications **111**
 safety issues 110–112
 mild cognitive impairment (MCI) 102–103, **103**
 neuropathologic changes 2, 3, 105–106, 105
 amyloid beta plaques 2, 105–106, 105
 hippocampal sparing AD 106, 106
 in extreme old age 2
 inflammation 106
 limbic predominant AD 106, 106
 neuritic plaques 2, 3, 105–106, 105
 neurofibrillary tangles 2, 3, 105, 106
 pathophysiology 104
 amyloid beta production 7, 104, 104
 preclinical stages 102, **102**
 rapidly progressive dementia 130
 subtypes 4
 treatment options 244–245
amantadine 256
ampakines 273
amyloid 12–14
 filament formation 12
 amyloid cascade hypothesis 7
 amyloid plaques
 A β plaques, Alzheimer's disease 2, 105–106, 105
 A β production 104, 104
 neuritic plaques (NPs) 2, 3, 105–106, 105
 prion protein plaques 28
 amyloid precursor protein (APP)
 multiple sclerosis 239–240
 mutation 7, 41
 processing pathways 104, 104
 amyloid spines 12
 amyotrophic lateral sclerosis (ALS) 137, 138–139
 biomarkers 145–150, **145**
 global functional assessment 150, **150**
 neuroimaging 146–149, 147, 148, 149
 neurophysiological testing 143–144, 145–146
 respiratory function 149
 diagnosis 152
 diagnostic criteria **138**
 environmental factors 140
 epidemiology 137–138, **138**
 examination and investigations 150–152
 excitotoxicity 39, 41
 genetics 41, 140–141, 141
 management 152–154
 family-based and third-party care 154
 medications 152–153
 nutrition 153–154
 pulmonary management 153
 rehabilitation 154
 surgical treatment 154
 pathophysiology 139, 142–143, 142
 prodromal features 145
 prognosis 152
 androgen insensitivity, spinal and bulbar muscular
 atrophy 202
 androgen receptor (AR) 204
 AR gene CAG repeat expansion 203, 204
 animal models 15–17
 experimental transmission studies 18–19
 prion protein 29
 Huntington's disease 266–267, **266**
 Parkinson disease 46–47
 spinal and bulbar muscular atrophy 204
 spinal muscular atrophy 189–191, 190
 anosmia, dementia with Lewy bodies 85
 anti-androgen treatment 208–209
 anti-epileptic drugs 42
 antisense oligonucleotides (ASOs) 194
 aphasia
 Alzheimer's disease 104
 corticobasal degeneration 94–95
 frontotemporal dementia 116
 logopenic progressive (LPA) 116
 primary non-fluent (PNFA) 116
 apolipoprotein E (APOE) gene 107
 apoptosis, excitotoxic 39, 39
 apraxia
 corticobasal degeneration 94
 progressive apraxia 94–95
 multiple system atrophy 60
 arimocloamol 306
 ascorbic acid therapy 231–232
 astrocytic gliosis, prion diseases 28, 28
 ataxia telangiectasia (A-T) 296
 biomarkers 299
 cancer predisposition 300
 cerebellar versus extrapyramidal symptoms
 298–299
 diagnosis 299–300
 examination 299
 epidemiology 296
 pathophysiology 299
 prognosis 300
 spectrum of clinical phenotype 296, **297**
 A-T-like disorder (ATLD) caused by *MRE11*
 mutation 298, 300
 adult onset - early 297–298
 adult onset - later 298
 childhood onset - atypical 2297
 childhood onset - typical/classical
 296–297
 disparity of cellular and clinical
 phenotypes 298
 treatment options 300

- ataxin (ATXN) mutations 285, 287, 290–292
mutant expression reduction 292
- atherosclerotic changes 6, 7
- atlastin 170–171
mutations 229
- ATM mutations 296–300
- ATP7A mutations 228
- ATP7B mutations 324
- ATP13A2 mutations 322
- autoimmune encephalopathies 130–131
- axon pathfinding defects, hereditary spastic paraplegia 173–174
- axonal transection, multiple sclerosis 239–240, 240
mechanisms 240
- axonal transport defects, peripheral neuropathies 224–225, 228–229
- balance impairment, Huntington's disease 250–251
- balloon neurons 95, 96
- benign hereditary chorea 275
- Berardinelli–Seip congenital lipodystrophy type 2 (BSCL2) mutations 228
- beta-methylamino-L-alanine (BMAA) 140
- beta-propeller protein associated neurodegeneration (BPAN) 323
- biomarkers
Alzheimer's disease 87, **103**
amyotrophic lateral sclerosis 145–150, **145**
ataxia telangiectasia 299
corticobasal degeneration 97, 99
dementia with Lewy bodies 86–88, 87, 88
frontotemporal dementia 120
Huntington's disease 267–269, 268
Niemann–Pick diseases 304, 305
peripheral neuropathies 230
primary lateral sclerosis 145–150, **145**
prion diseases 31–32
CJD 32, 128
progressive supranuclear palsy 77
spinal muscular atrophy 196
X-linked adrenoleukodystrophy 311
- bipolar symptoms, Huntington's disease 252
- bone morphogenetic protein (BMP) signaling 173
- botulinum toxin 99, 320
- bovine spongiform encephalopathy (BSE) 25, 31, 126
- bradykinesia, Huntington's disease 250
- brain aging 1
genetic factors 6–8
pathologies 1–5
- brain health tips **109**
- brain iron accumulation disorders *see*
neurodegeneration with brain iron accumulation (NBIA)
- brain-derived neurotrophic factor (BDNF) 271, 272–273
- Bunina bodies 142, 142
- c2orf37* mutations 322
- c9orf72* mutations 119, 141, 142, 142, 274
- c19orf12* mutations 321
- CAG repeat expansions
Huntington's disease 259–260, 260
spinal and bulbar muscular atrophy 203, 204
spinocerebellar ataxias 284, 288
- cell transplantation, Huntington's disease 273
- central motor conduction time (CMCT) 146
- cerebellar cortical degeneration, spinocerebellar ataxia 286
- cerebellar syndrome, multiple system atrophy 60
- cerebral X-linked adrenoleukodystrophy
adolescent 309
adult 309
childhood 309
neuropathology 310
- cerebrospinal fluid investigations
amyotrophic lateral sclerosis 151–152
corticobasal degeneration 97
dementia with Lewy bodies 86
prion diseases 32, 128
rapidly progressive dementias 133
- cerebrovascular disease (CVD) 5, 6, 7
- ceruloplasmin 318
mutations 317, 318
- CHAC mutations 275
- Charcot's disease 137
- Charcot–Marie–Tooth disease (CMT) 219
biomarkers 230
classification **220–221**
diagnosis 230–231, 231
investigation 230
molecular genetics 222–227
axonal transport 224–225
endocytic protein recycling 225–226
ion channels 226
mitochondrial fusion and fission 224
myelin structural components 222–223
protein synthesis 224
transcription factors and gene expression regulators 223–224
prognosis 219
treatment options 231–232
future developments 232–233
- charged multivesicular body protein 2B (CHMP2B) mutations 119
- childhood cerebral adrenoleukodystrophy (CCALD) 309
see also X-linked adrenoleukodystrophy
- cholinesterase inhibitors, dementia with Lewy body management 89–90
- chorea 248, 275
benign hereditary 275
Huntington's disease 250, 256
management 256
see also movement disorders
- chorea–acanthocytosis 275
- chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) 229–230
- chronic wasting disease of deer and elk (CWD) 31
- CJB1* mutations 223
- clonazepam 99, 256
- CoA synthase protein-associated neurodegeneration (CoPAN) 323
- cognitive impairment 1–5
Alzheimer's disease 102–103, 107–109
amyotrophic lateral sclerosis 139, 145, 150, 151
corticobasal degeneration 93
dementia with Lewy bodies 84–86, 88
Huntington's disease 251, 257
mild (MCI) 102–103
multiple sclerosis 242–243
multiple system atrophy 60
neurodegeneration with iron accumulation 319, 323
Parkinson disease 47, 53, 54
primary lateral sclerosis 139, 150
prion diseases 25, 126, 134
progressive supranuclear palsy 72–73
rapidly progressive dementias 129, 132
X-linked adrenoleukodystrophy 311
- continence problems, Huntington's disease 251, 258
- copper chelation therapy 324
- corpora amylacea 5, 7
- cortical degeneration, spinocerebellar ataxia 286
- cortical demyelination, multiple sclerosis 242–243, 243
- corticobasal degeneration (CBD) 74, 93, 130
associated syndromes 94–95
biochemistry 95
biomarkers 97, 99
diagnosis 98
epidemiology 93
future developments 99
genetics 95
imaging studies 97–98, 97, 98
laboratory investigations 97
pathophysiology 95, 96
prognosis 98
spectrum of clinical phenotype 93–94
symmetric 94
treatment 99
- corticobasal syndrome (CBS) 78, 94, 99
- corticospinal tract 162
- CRASH syndrome 163
- Creutzfeldt–Jakob disease (CJD) 25, 127
biomarkers 32, 128
clinical prodrome 128
diagnosis 32, **33**, 128–129
epidemiology 127
examination and investigations 32
familial (fCJD) 26–28, **26**
genetics 31, 127
histopathologies 27–28, 28
iatrogenic (iCJD) 25, 27, 31, 127–128
imaging 128
protease-resistant PrP typing 29
sporadic (sCJD) 25, 27–28
subtypes 29
strains 127
variant (vCJD) 25, 27, 28, 127, 129–130
see also prion diseases
- crystalline oligodendrogliopathy 162
- curcumin 232
- cyanotoxin exposure 140
- cydad plant toxin 39
- cyclodextrin 306
- davunetide 79
- deep brain stimulation (DBS), Parkinson disease 53, 54
- dementia
age-related prevalence 2
agitation management 112
Alzheimer's disease 103, **103**
differential diagnosis **109**
neurodegeneration with brain iron accumulation 319, 322
rapidly progressive 130
semantic (SD) 116
see also dementia with Lewy bodies (DLB); frontotemporal dementia (FTD); rapidly progressive dementias (RPD)
- dementia with Lewy bodies (DLB) 4, 4, 16–17, 83
 α -synuclein deposits 4, 4
biomarkers 86–88, 87, 88
clinical features 83, 84
spectrum of clinical phenotypes 84–85
diagnosis 88–89
diagnostic criteria **84**
environmental factors 86

- epidemiology 83–84
 future developments 90
 genetics 86
 imaging studies 87, 87, 88
 pathophysiology 85–86, 85, 86
 prognosis 89
 treatment options and management 89–90, 89
- demyelination
 chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) 229–230
 Guillain–Barré syndrome 230
 multiple sclerosis 239–243
 axonal degeneration 241–242, 241
 axonal transection 239–240
 cortical and deep gray matter 242–243, 243
- dentato-pallido-rubro-lusian atrophy (DRPLA) 274
- depression
 Alzheimer's disease 107, 108
 dementia with Lewy bodies 84, 90
 Huntington's disease 252, 257
- DIDMOAD (Wolfram) syndrome 216
- dietary factors
 Alzheimer's disease 107
 excitotoxicity 41, 42
- dietary interventions 42
 energy restriction 41, 42
see also nutrition management
- diffusion tensor imaging (DTI)
 amyotrophic lateral sclerosis 147, 148
 corticobasal degeneration 97
- dimethyl fumarate 244
- distal hereditary motor neuropathy (dHMN)
 219, 221
 classification 227
 diagnosis 231
 molecular genetics 227–228
- DNA methyltransferase 1 (*DNMT1*) mutations 229
- dominant optic atrophy 213–215
 clinical features 214, 214
 genetics 215
 investigations 215
- domoic acid 37
- dopamine transporter imaging
 corticobasal degeneration 98, 98
 dementia with Lewy bodies 87, 87
 Kufor Rakeb syndrome 322
- doxycycline 34
- driving considerations
 Alzheimer's disease 110–111
 Huntington's disease 261–262
- drugs that may cause memory loss 110
- dry steric zipper 12
- dynactin (DCTN1) protein 228
- dynamain 2 (*DNM2*) mutations 225
- dynein, cytoplasmic 1, heavy chain 1 (*DYNC1H1*) 225
- dysarthria, multiple system atrophy 60
- dysautonomia, Huntington's disease 251
- dysphagia
 amyotrophic lateral sclerosis 139
 Huntington's disease 251
 multiple system atrophy 60
- dyspnea, amyotrophic lateral sclerosis 139
- dystonia
 corticobasal degeneration 94
 Huntington's disease 250
 management 256–257, 257
 manganism 323
 multiple system atrophy 59
- neurodegeneration with brain iron accumulation 317, 319–323
 Wilson disease 324
- EGR2* mutations 223
- electrical impedance myography (EIM) 146
- electrocardiography (ECG), spinal and bulbar muscular atrophy 206–207
- electroencephalography (EEG)
 prion diseases 32
 rapidly progressive dementias 133
- electromyography (EMG)
 amyotrophic lateral sclerosis 143–144, 145–146, 151
 peripheral neuropathies 230
 spinal and bulbar muscular atrophy 206
 spinal muscular atrophy 183–184
- employment considerations, Huntington's disease 261
- end-of-life care *see* palliative care
- endocytic protein recycling defect, peripheral neuropathies 225
- endoplasmic reticulum (ER) 170–171
 hereditary spastic paraplegia protein interactions 171
- endosomal sorting complex required for transport (ESCRT) 170
- endosomal trafficking deficiency 304–306
- epigenetic changes, Parkinson disease 47
- epilepsy 37, 41
see also excitotoxicity
- excitotoxicity 37, 38
 definition 37
 disease-specific pathophysiology 39–41, 39
 glutamate receptor activation 40
 oxidative stress 40–41
 sodium and calcium influx 40
 environmental influences 41–42, 42
 future developments 42, 43
 genetics 41
 Huntington's disease 265–266
 multiple sclerosis 240
 treatment approaches 42
- exendin 42, 48
- exercise benefits 41–42, 107, 108
- eye movement abnormalities
 Huntington's disease 251
 progressive supranuclear palsy 72, 73
- FA2H* mutations 317, 322–323
- facial-onset sensory and motor neuronopathy (FOSMN) syndrome 207
- FAM134B* mutations 229
- familial amyloid polyneuropathy (FAP) 229
- familial CJD (fCJD) 26
PRNP mutations 26, 26, 127
see also Creutzfeldt–Jakob disease (CJD)
- fatal insomnia (FI) 25, 27
 histopathology 28, 28
see also prion diseases
- ferritin 318
- ferritin light chain (*FTL*) mutation 317, 318
- fetal acid hydroxylase (*FA2H*) 322
 mutations 317, 322–323
- FGD1-related F-actin binding protein (*FGD4*) mutation 225
- fibulin-5 (*FBLN5*) mutations 227
- FIG4* mutations 141, 226
- fingolimod 244, 245
- flupirtine 34
- forced vital capacity (FVC) 149
- frataxin 215
- Friedreich's ataxia 215
- frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) 15, 116–117, 117, 118
MAPT mutations 15, 75–76
- frontotemporal dementia (FTD) 115, 130
 Alzheimer's disease and 104
 clinical prodrome and biomarkers 120
 diagnosis 121
 epidemiology 115
 excitotoxicity 41
 future developments 121–122
 genetics 118–119
 imaging 120–121
 pathology 119–120, 120
 prognosis 121
 spectrum of clinical phenotype 115–117
 behavioral variant (bvFTD) 116, 116
 FTD with motor neuron disease (FTD-MND) 117
 FTD with parkinsonism linked to chromosome 17 (FTDP-17) 116–117, 117, 118
 lopogetic progressive aphasia (LPA) 116
 primary non-fluent aphasia (PNFA) 116
 semantic dementia (SD) 116
 TDP-43 positive FTD 5
 treatment options 121
see also frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)
- fused in sarcoma (*FUS*) mutations 119, 141, 143
- gait disturbance
 ataxia telangiectasia 296
 manganism 323
 neurodegeneration with brain iron accumulation 317, 319, 321, 322
 progressive supranuclear palsy 73, 74
see also movement disorders
- gap junction protein beta 1 (*GJB1*) mutations 223
- GARS* mutations 224, 227
- Gaucher disease 47
- GDAP1* mutations 224
- gene silencing, Huntington's disease 269–271
- gene therapy
 Parkinson disease 54–55
 spinal muscular atrophy 195
 X-linked adrenoleukodystrophy 314
- genetic testing
 Huntington's disease 255–256
 neurodegeneration with brain iron accumulation 320, 323
 peripheral neuropathies 230
 spinal and bulbar muscular atrophy 207
 spinal muscular atrophy 184, 184
- Gerstmann–Sträussler–Scheinker disease (GSS)
 25, 27
 genetics 31
 histopathology 28, 28
see also prion diseases
- giant axonal neuropathy 229
- gigaxonin (*GAN*) mutations 229
- glial cytoplasmic inclusions (GCIs) 17
 amyotrophic lateral sclerosis 142, 142
 multiple system atrophy 61–62, 61, 62
- glial-derived neurotrophic factor (GDNF) infusion, Parkinson disease 54
- gliosis, prion diseases 28, 28

- globus pallidus deep brain stimulation, Parkinson disease 53
 glucagon-like peptide 1 (GLP-1) analogs 42
 glucocerebrosidase (GBA) 47
 mutations 86–87
 glutamate receptor activation 37, 38, 40
 glycyl t-RNA synthetase (*GARS*) mutations 224, 227
 granulin (*GRN*) mutation, frontotemporal dementia 117, 117, 119
 gray matter demyelination, multiple sclerosis 242–243
 growing rods 186
 Guam syndrome 39
 Guillain-Barré syndrome (GBS) 229–230

 hallucinations, dementia with Lewy bodies 84
 management 90
 Hashimoto's encephalopathy (HE) 131
 head trauma *see* traumatic brain injury (TBI)
 heat shock proteins (HSPs) 204, 226
 mutations 226, 228
 hematopoietic stem cell transplantation *see* stem cell therapy
 hepatosplenomegaly, Neumann-Pick disease 303, 304, 305
 hereditary motor and sensory neuropathy (HMSN) 215, 219
 HMSN-Russe 227
 hereditary neuralgic amyotrophy (HNA) 221, 221, 229
 hereditary neuropathy with liability to pressure palsies (HNPP) 219
 classification 221
 genetics 222–227
 hereditary sensory and autonomic neuropathy (HSAN) 219–221, 221
 classification 228
 diagnosis 232
 molecular genetics 228–229
 hereditary spastic paraplegia (HSP) 161
 cytopathology 168–174
 axon pathfinding 173–174
 lipid droplet defects 171–172
 membrane modeling and organelle morphogenesis 168–173, 169
 mitochondrial function 173
 myelination 174
 identified gene products 169–170
 motor-based transport 173
 neuropathology 161–163, 162
 optic neuropathy 216
 specific syndromes 163–168, 164
 hippocampal sclerosis (HS) 4, 5
 see also HS-Aging
 hippocampal sparing Alzheimer's disease 106, 106
 histone deacetylase (HDAC) inhibitors 193
 HS-Aging 4–5
HSN2 gene 229
 huntingtin (HTT) 259, 262–265, 277
 CAG repeat length 259–260, 260
 clearance of mutant huntingtin 265
 enhancement of 269–272
 gene mutations 41, 248, 259
 gene silencing approach 270–2711
 metabolic effects 265
 mitochondrial pathology and 265
 post-translational modifications 264
 protein misfolding and proteolysis 264
 quantification 269
 transcriptional dysregulation and 265
 vesicular trafficking role 265
 Huntington's disease (HD) 248
 animal models 266–267, 266
 cell models 266
 clinical features 249–254, 250
 cardiac 253
 cognitive 251
 metabolic/endocrine 252–253
 musculoskeletal 253
 neurological 249–251
 neuropsychiatric 251–252, 251
 reproductive pathology 253
 diagnosis 255–256
 examination 255
 genetic testing 255–256, 260, 261
 investigations 255–256
 driving considerations 261–262
 employment considerations 261
 epidemiology 248, 249
 excitotoxicity 41
 future directions 276–277
 genetics 259–262
 genetic counseling 260–261, 260
 insurance implications 261
 predictive genetic testing 261
 historical milestones 248
 management 256–259, 258, 275–276
 movement disorder 256–257, 257
 psychiatric disorders 257, 258
 onset 249
 pathology 262–266
 neuropathology 262
 pathogenesis 262–266, 263, 264
 premanifest phase 253–254
 prenatal testing 261, 262
 stages of 254, 254
 therapy development 267–273
 biomarkers 267–269, 268
 cell transplantation 273
 challenges 267
 clinical trials 269, 270
 inflammation reduction 272
 mitochondrial protection 273
 mutant huntingtin clearance enhancement 269–272
 neurotrophic support 272–273
 post-translational modification 273
 restoring connectivity 272
 restoring gene regulation 272
 variants 254–255
 akinetic-rigid or Westphal variant 255
 juvenile-onset Huntington's disease 255
 late-onset Huntington's disease 254–255
 Huntington's disease phenocopy syndromes 273–275, 273, 274
 genetic testing 276, 276
 HD-like syndrome 1 (HDL1) 273–274
 HD-like syndrome 2 (HDL2) 274
 24S-hydroxycholesterol (24OHC) 268
 6-hydroxydopamine (6-OHDA) 46
 4-hydroxynonenal 40
 hydroxyurea 193–194

IGHMBP2 mutations 227–228
IKBKAP mutations 228–229
 incontinence, Huntington's disease 251, 258
INF2 mutations 225
 infantile neuroaxonal dystrophy (INAD) 320–321
 infarcts 6

 inflammation
 Alzheimer's disease 106
 Huntington's disease 265
 reduction 272
 multiple sclerosis 239–240
 Parkinson disease 48–49
 iron chelation or depletion therapy 319
 see also neurodegeneration with brain iron accumulation (NBIA)

 kainic acid 37
 Kennedy disease *see* spinal and bulbar muscular atrophy (SBMA)
 kinase complex-associated protein (*IKBKAP*) mutations 228–229
 kinesin family member mutations 225, 228
 Kurof Rakeb syndrome (KRS) 322
 kuru 126
 kynurenine pathway 266, 272

L1CAM mutations 173–174
 lamin gene (*LMNA*) mutations 6
 Leber's hereditary optic neuropathy (LHON) 211–213
 clinical course and prognosis 212
 clinical features 211–212, 212, 213
 genetics 213
 investigations 212
 pathogenesis 213
 treatment 213
 leucine rich repeat and sterile alpha motif 1 (*LRSAMI*) mutations 225
 leuprorelin 208–209
 levodopa therapy
 corticobasal degeneration 99
 dementia with Lewy bodies 89
 Lewy bodies 4, 12, 83
 α -synuclein filaments 16–17
 dementia with Lewy bodies 83, 85–86, 85
 distribution in Parkinson disease 49
 Lewy body dysphagia 17
 Lewy neurites 4, 12
 limbic predominant Alzheimer's disease 106, 106
 lipid droplet defects, hereditary spastic paraplegia 171–172
 lipohyalinosis 7
 Lison syndrome 165
LITAF/SIMPLE mutations 226
 lithium therapy 16, 79
LMNA mutations 223
 logopenic progressive aphasia (LPA) 116
 Lorenzo's oil 313
 Lou Gehrig's disease 137
 lovastatin 313
 LRRK2 mutations 47
LRSAMI mutations 225
 lysosomal trafficking deficiency 304–306

 Machado-Joseph disease (MJD) 285, 290
 Macleod syndrome 275
 magnetic resonance imaging (MRI)
 amyotrophic lateral sclerosis 146–147, 147
 functional MRI 147–149, 149
 corticobasal degeneration 97–98
 Creutzfeldt-Jakob disease 128
 frontotemporal dementia 120–121
 Huntington's disease 268
 multiple system atrophy 64, 65
 neurodegeneration with brain iron accumulation 318–319, 321, 323

- peripheral neuropathies 230
 primary lateral sclerosis 147
 prion diseases 32
 rapidly progressive dementias 132, 133
 spinocerebellar ataxia 287–288, 288
 X-linked adrenoleukodystrophy 312, 312, 313
- magnetic resonance spectroscopy (MRS)
 Huntington's disease 268
 X-linked adrenoleukodystrophy 313
- manganism 323–324
- MAPT* gene 15, 74–75
 haplotypes 15
 mutations 12, 13
 frontotemporal dementia 118, 121
 frontotemporal dementia and parkinsonism
 linked to chromosome 17 (FTDP-17) 15,
 75–76, 116–117, 117
 multiple system atrophy 63
 progressive supranuclear palsy 74–76
- MASA syndrome 163
- Mast syndrome 165
- mechanical ventilation 153
- MED25* mutations 223
- memantine 39, 42
- 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
 (MPTP) 39, 46
- MFN2* mutations 215, 224
- micro-RNAs (miRNAs), role in Parkinson
 disease 47
- microglial activation, multiple system atrophy 63
- microtubule-associated protein (MAP) 14
see also MAPT gene
- miglustat 306
- mild cognitive impairment (MCI), Alzheimer's
 disease 102–103
 criteria 103, 103
- mitochondria 213
- mitochondrial dysfunction 213
 hereditary spastic paraplegia 173
 Huntington's disease 265
 protection 273
 Parkinson disease 47, 48
 peripheral neuropathies 224
- mitochondrial membrane protein associated
 neurodegeneration (MPAN) 317,
 321–322
 diagnosis 321–322
 investigations 321
 pathophysiology 321
 spectrum of clinical phenotype 321
- mitofusin (MFN1/2)
 as therapeutic target 232–233
 mutations 215, 224
- Mohr-Tranebjaerg syndrome 216
- motor evoked potentials (MEP) 146
- motor neuron disease (MND) 137
 frontotemporal dementia with MND
 (FTD-MND) 117
 nomenclature 138
 relationships between diseases 138
see also amyotrophic lateral sclerosis (ALS);
 primary lateral sclerosis (PLS)
- motor unit estimates (MUNE) 146
- movement disorders 248
 drug management 257
 neurodegeneration with brain iron accumulation
 317–323
 Wilson disease 324
see also chorea; gait disturbance; Huntington's
 disease (HD); Parkinson disease (PD)
- MPZ* mutations 223
- MRE11* mutation 298, 300
- MTMR* mutations 225–226, 225
- mTOR activation 272
- multiple sclerosis (MS) 238
 axonal degeneration 240–242, 241
 mechanisms 241–242
 axonal transection 239–240, 240
 mechanisms 240
 cortical and gray matter demyelination
 242–243, 243
 environmental factors 239
 epidemiology 238
 future developments 245
 genetics 239
 neurodegeneration 239
 primary progressive MS (PPMS) 238
 relapsing-remitting MS (RRMS) 238
 secondary progressive disease phase
 (SPMS) 238
 spectrum of clinical phenotype 238–239
- multiple system atrophy (MSA) 17, 58
 diagnosis 65
 diagnostic criteria 59
 environmental risk factors 63
 epidemiology 58
 genetics 63
 investigations 64
 imaging 64, 65
 motor disturbances 59–60
 non-motor symptoms 60
 pathophysiology 60–63, 61, 62
 clinicopathological correlations 62
 prognosis 66
 subtypes 58, 60
 treatment options 66
 future developments 66–67
 non-medical treatment 66
 symptomatic management 67
- muscle biopsy, spinal and bulbar muscular atrophy
 206, 207
- muscle cramp management 208
- muscle ultrasonography 149
- muscular atrophy, Huntington's disease 253
see also spinal and bulbar muscular atrophy
 (SBMA); spinal muscular atrophy (SMA)
- myelin alterations
 inherited peripheral neuropathies 222–223
 multiple system atrophy 63
- myelin protein zero (*MPZ*) mutations 223
- myelination defects, hereditary spastic
 paraplegia 174
- myoclonus
 CJD 25
 corticobasal degeneration 94
- myotubularin-related protein (*MTMR*) mutations
 225–226, 225
- N*-acetyl-L-cysteine 314
- natalizumab 244, 245
- NDRG1* mutations 227
- necrosis, excitotoxic 39, 39
- nerve growth factor beta (NGFB) mutations 229
- neuritic plaques (NPs) 2, 3, 12
- neuroacantocytosis 275
- neurodegeneration with brain iron accumulation
 (NBIA) 274, 275, 317
 aceruloplasminemia 318–319
 beta-propeller protein associated
 neurodegeneration (BPAN) 323
- CoA synthase protein-associated
 neurodegeneration (CoPAN) 323
- epidemiology 317
- FA2H* associated NBIA 322–323
- Kurof Rakeb syndrome 322
- mitochondrial membrane protein associated
 neurodegeneration (MPAN) 321–322
- NBIA1 274–275
- NBIA2 275
- neuroferritinopathy 317–318
- pantothenate kinase associated
 neurodegeneration (PKAN) 319–320
- phospholipase A2 (*PLA2G6*) mutation associated
 neurodegeneration (PLAN) 320–321
- Woodhouse-Sakati syndrome (WSS) 322
- neuroferritinopathy 317–318
 diagnosis 318
 investigations 318
 pathophysiology 318
 spectrum of clinical phenotype 317
- neurofibrillary tangles (NFTs) 12
 Alzheimer's disease 2, 3, 105, 106
 progressive supranuclear palsy 74
- neuroinflammation, Parkinson disease 48–49
- neurophysiological index (NI) 146
- neuroprotective measures
 multiple sclerosis 245
 multiple system atrophy 66
 spinal muscular atrophy 195
- neurotransplantation, multiple system
 atrophy 66
- neurotrophic tyrosine kinase receptor 1 (NTRK1)
 mutations 221, 221, 229
- NF-L* mutations 224–225
- NGFB* mutations 229
- Niemann-Pick disease (NPD) 303
 types A and B 303–304
 biomarkers 304
 clinical prodrome 304
 diagnosis 304
 epidemiology 303
 future developments 304
 pathology 303–304
 spectrum of clinical phenotypes 303
 treatment options 304
- type C 304–306
 biomarkers 305
 clinical prodrome 305
 diagnosis 305–306
 epidemiology 304
 future developments 306
 pathology 305
 prognosis 306
 spectrum of clinical phenotype 304–305
 treatment options 306
- 3-nitropropionic acid (3NP) 39
- non-paraneoplastic limbic encephalopathy
 (LE) 130
- noninvasive ventilation (NIV) 153, 185
- NPCI/2* mutations 305
- NTRK1 mutations 221, 221, 229
- nutrition management
 amyotrophic lateral sclerosis 153–154
 spinal muscular atrophy 185–186
see also dietary interventions
- obsessive-compulsive disorder, Huntington's disease
 252, 257
- oculomotor dysfunction, multiple system
 atrophy 60

- olanzapine 256
- olivopontocerebellar atrophy (OPCA) 58, 60, 286
- optic neuropathies 211
 - dominant optic atrophy 213–215, 214
 - Friedreich's ataxia 215
 - hereditary neuropathy association 215
 - hereditary spastic paraplegia (HSP) 216
 - Leber's hereditary optic neuropathy (LHON) 211–213, 212
 - Mohr–Tranebjaerg syndrome 216
 - spinocerebellar ataxias 215
- orthopedic management, spinal muscular atrophy 186
- osteopenia, spinal muscular atrophy 186
- oxidative stress
 - excitotoxicity and 40–41
 - Parkinson disease 48
- oxysterols, Neumann–Pick disease 305
- p62/sequestosome 1 mutations 119
- palliative care
 - amyotrophic lateral sclerosis 154
 - corticobasal degeneration 99
 - prion diseases 34
 - progressive supranuclear palsy 78
 - rapidly progressive dementias 134
 - spinal muscular atrophy 186
- pallidotomy, Parkinson disease 53–54
- pantothenate kinase 2 (PKAN2) mutations 317, 319–320
- pantothenate kinase associated neurodegeneration (PKAN) 319–320
 - investigations 320
 - pathophysiology 319–320
 - spectrum of clinical phenotype 319
 - treatment options 320
- Papp–Lantos inclusions 17, 61
- paraneoplastic limbic encephalopathy (PLE) 130, 134
- parkin mutations 47–49
- Parkinson disease (PD)
 - environmental risk factors 50
 - pesticide exposure 39, 50
 - excitotoxicity 41
 - experimental models 46–47
 - stem cell culture models 46–47
 - gene therapy 54–55
 - genetics 41, 46, 47
 - inflammation role 48–49
 - Lewy body distribution 49
 - mitochondrial dysfunction 47, 48
 - SNCA mutations 16
 - surgical therapy 53–55
 - deep brain stimulation (DBS) 53, 54
 - experimental surgery 54–55
 - pallidotomy 53–54
 - patient selection 54
 - pedunculopontine area as target 54, 55
- parkinsonism
 - corticobasal degeneration 93
 - dementia with Lewy bodies 84
 - manganism 323
 - multiple system atrophy 59
 - neurodegeneration with brain iron accumulation 320–323
- pedunculopontine nucleus complex 54, 55
- Pelizaeus–Merzbacher disease (PMD) 174
- pentosan polysulfate (PPS) 33–34
- periaxin (PRX) mutations 223
- peripheral nervous system 218
 - peripheral neuropathies 218
 - biomarkers 230
 - causes of 218–219
 - classification 220–221
 - diagnosis 230–231, 231, 232
 - investigation 230
 - molecular genetics 222–230
 - next-generation sequencing 232
 - prognosis 219
 - spectrum of phenotypes 219
 - treatment options 231–232
 - future developments 232–233
 - pesticide exposure 39, 50, 140
 - PGC-1 α 48
 - phenylbutyrate (PB) 193
 - phospholipase A2 (PLA2G6) mutation associated neurodegeneration (PLAN) 320–321
 - investigations 321
 - pathophysiology 321
 - spectrum of clinical phenotype 320–321
 - phospholipase A2 (PLA2G6) mutations 317, 321
 - Pick bodies 12
 - Pick disease 12, 115
 - see also* frontotemporal dementia (FTD); Niemann–Pick disease (NPD)
 - PINK1 mutations 47–49
 - PLP1 mutations 174
 - PMP22 mutations 222
 - POLG1 mutations 227
 - polyglutamine diseases 203–204
 - positron emission tomography (PET)
 - Alzheimer's disease 109, 110, 111
 - corticobasal degeneration 98, 98
 - dementia with Lewy bodies 87, 88
 - frontotemporal dementia 121
 - Huntington's disease 268
 - prion diseases 32
 - postural deficits, Huntington's disease 250–251
 - PREDICT-HD study 268
 - prenatal testing, Huntington's disease 261, 262
 - presenilin-1 (PSEN1) mutations 6, 41, 106
 - primary acid sphingomyelinase deficiencies 303–304
 - primary lateral sclerosis (PLS) 137, 139
 - biomarkers 145–150, 145
 - neuroimaging 146–149, 148
 - neurophysiological testing 145–146
 - diagnosis 152
 - epidemiology 137
 - examination and investigations 150–151
 - genetics 141–142
 - pathology 143–145
 - prodromal features 145
 - prognosis 152
 - primary non-fluent aphasia (PNFA) 116
 - prion diseases 25, 49, 126
 - clinical prodrome and biomarkers 31–32
 - diagnosis 32, 33, 134
 - environmental factors 31
 - epidemiology 126
 - examination and investigations 32
 - experimental transmission studies 29
 - future developments 34, 129
 - genetics 30–31, 127
 - pathogenesis 29–31
 - pathophysiology 27–31, 127
 - histopathology 27–28, 28
 - phenotypes 26
 - prognosis 32, 134
 - social and family burden 129
 - spectrum of clinical phenotype 25, 126–127
 - treatment options 129, 134
 - medical treatments 33–34
 - see also specific diseases*
 - prion protein (PrP)
 - amyloid plaques 28
 - anti-PrP antibody therapy 34
 - propagation 29, 30
 - protease-resistant PrP typing 28–29, 29
 - protein misfolding conversion assay (PMCA) 29
 - PRNP mutations 26, 26, 30–31, 127
 - progerias 6
 - progressive supranuclear palsy (PSP) 72, 130
 - clinical features 72–73
 - clinical prodrome and biomarkers 77
 - definition 72
 - diagnosis 73, 78
 - environmental factors 77
 - epidemiology 73
 - examination and investigations 77–78
 - future developments 78–79
 - genetics 76–77
 - histopathology 74, 75
 - molecular pathology 74–76
 - prognosis 78
 - spectrum of clinical phenotype 74
 - treatments 78
 - progressive supranuclear palsy-Richardson's syndrome (PSP-RS) 72, 74, 94
 - protein misfolding conversion assay (PMCA) 29
 - PRX mutations 223
 - psychotic symptoms
 - Alzheimer's disease 108
 - dementia with Lewy bodies 84, 90
 - Huntington's disease 252, 257
 - prion disease 33
 - pulmonary disease *see* respiratory problems
 - pure autonomic failure 17
 - pyramidal signs, multiple system atrophy 60
- quinacrine 33
- quinazolines 194
- RAB7 mutations 226, 229
- rapid eye movement sleep behavior disorder (RBD), dementia with Lewy bodies 84–85
 - management 90
- rapidly progressive dementias (RPD) 129
 - causes 129–130, 130
 - diagnosis 134
 - epidemiology 129
 - examination 131–132
 - imaging studies 132, 133
 - laboratory investigations 132–134, 133
 - pathophysiology 130–131
 - autoimmune encephalopathies 130–131
 - neurodegenerative disorders 130
 - prognosis 134
 - spectrum of clinical phenotype 129–130
 - treatment options 134
 - see also* prion diseases
- reactive oxygen species (ROS) *see* oxidative stress
- rehabilitation, amyotrophic lateral sclerosis 154
- remyelination, multiple sclerosis 245
- respiratory problems
 - multiple system atrophy 60
 - respiratory function evaluation 149
 - spinal muscular atrophy 185
- resveratrol (RSV) 48

- RIDDLE syndrome 298
 rigidity, Huntington's disease 250, 256
 riluzole 39, 42
 RNA interference (RNAi) 270
- scrapie 31, 126
 semantic dementia (SD) 116
 senataxin (*SETX*) mutations 227–228
 senescence 1
 senile plaques, Alzheimer's disease 105–106
 see also amyloid plaques
 septin 9 (*SEPT9*) mutations 229
 sequestosome 1 (*SQSTM1*) mutations 119
 serine palmitoyltransferase mutations 229
 Shy-Drager syndrome 58
 Silver syndrome 164
 single photon emission computer tomography (SPECT)
 corticobasal degeneration 98, 98
 dementia with Lewy bodies 87, 87
 SIRT1 48
 sirtuins 272
 sleep disorders
 Alzheimer's disease 108
 dementia with Lewy bodies 84–85, 87–88
 management 90
 Huntington's disease 251, 257–258
 multiple system atrophy 60
 slow vital capacity (SVC) 149
 SMN genes 186
 expression 187
 mutations 179, 184, 184
 protein product 179, 187
 stabilization 194–195
 splicing 186–187
 therapeutic activation 193–194
 see also spinal muscular atrophy (SMA)
- smoking association 140
 SNARE complexes 16
 SNCA mutations 12, 13
 dementia with Lewy bodies 86
 multiple system atrophy 63
 Parkinson disease 16, 47
 see also alpha-synuclein
 sniff inspiratory pressure (SNIP) 149
 SOD1 mutations 141, 143
 spastic paraplegia syndromes *see* hereditary spastic paraplegia (HSP)
 spastin 168–170
 spastizin 172
 spatascin 172
 sphingolipid metabolism 229
 spinal and bulbar muscular atrophy (SBMA) 202
 animal model 204
 clinical features 202, 206
 diagnosis 207
 epidemiology 202
 examination 204–205, 205
 future developments 209
 genetic testing 207
 genotype–phenotype correlations 202–203
 laboratory investigations 206–207, 207
 pathology and pathogenesis 203–204, 203
 prognosis 207–208
 treatment options 208
 anti-androgen treatment 208–209
 spinal muscular atrophy (SMA) 179
 animal models 189–191
 Drosophila 189
 mouse 190–191, 190
 pig 191
 zebrafish 190
 classification 180
 clinical characteristics 180, 181
 diagnosis 182–184
 clinical investigation 182–184
 genetic testing 184, 184
 disease course 181–182
 disease mechanisms 191–192
 epidemiology 179–180
 genetic basis 179, 180, 186
 see also SMN genes
 management 185–186
 nutrition 185–186
 orthopedics 186
 palliative care 186
 respiratory disease 185
 pathophysiology 182, 183, 186–189, 187, 188
 therapeutics development 192–196, 192, 193
 biomarkers 196
 clinical trial development 195
 gene therapy 195
 neuroprotection 195
 outcome measures 195–196
 promotion of exon 7 inclusion in SMN2-derived transcripts 194
 SMN protein stabilization 194–195
 SMN2 gene activation 193–194
 stem cell therapy 195
 type 0 180
 type 1 180–181
 type 2 181
 type 3 181
 type 4 181
 see also spinal and bulbar muscular atrophy (SBMA)
- spinocerebellar ataxias (SCA) 215, 274, 284, 285
 clinical features 284, 285
 diagnosis 287–288
 epidemiology 284
 genetics 288
 neuropathology 286
 pathogenesis 288–292, 289
 pathological features 287
 SCA1 286, 287, 291
 SCA2 286, 287, 290–291
 SCA3 285–286, 287, 290
 SCA6 286, 287, 292
 SCA7 286, 287, 291–292
 treatment approaches 292
 spongiform degeneration 27–28, 28
 SPTLC1/2 mutations 229
 static encephalopathy with neurological deterioration in adulthood (SENDA) syndrome 323
 stem cell culture models, Parkinson disease 46–47
 stem cell therapy
 multiple system atrophy 66–67
 Niemann–Pick disease 304
 spinal muscular atrophy 195
 X-linked adrenoleukodystrophy 313–314
 steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT) 131
 striatonigral degeneration 58, 60
 Strümpell disease *see* hereditary spastic paraplegia (HSP)
 strumpellin 172
 subthalamic nucleus (STN) deep brain stimulation, Parkinson disease 53, 54
 suicidality, Huntington's disease 252
- sulpiride 256
 survival motor neuron (SMN) protein 179, 187
 see also SMN genes
 synapse loss 2
 synucleinopathies 12, 16–17
 animal models 17
 experimental transmission studies 18–19
 see also alpha-synuclein (α -SN)
 synucleins 16
 lipid-binding 16
 see also alpha-synuclein (α -SN); synucleinopathies
- t-RNA synthetase mutations 224
 TANK-binding kinase 1 (*TBK1*) mutations 119
 TARDBP mutations 141
 tau kinase inhibitors 16
 progressive supranuclear palsy 78–79
 tau protein 12, 74–75
 aggregation 14
 degradation 20
 therapeutic implications 19–20
 genetics 15
 see also MAPT gene
 isoforms 13, 14
 filament composition 15
 phosphorylation 14–15
 therapeutic targeting 16
 progressive supranuclear palsy 75–76
 tau-directed therapies 99
 see also tau kinase inhibitors
 tauopathies 12, 14–16, 95
 animal models 15–16
 experimental transmission studies 18–19
 TDP-43 abnormalities 4–5, 142, 142
 HS-Aging 4–5
 teriflunomide 244
 tetrabenazine 256
 tiapride 256
 tongue atrophy, spinal and bulbar muscular atrophy 204, 205
 tracheostomy 154
 with mechanical ventilation (TMV) 153
 TRACK-HD study 268, 269
 transactive response DNA binding protein 43 (*TARDBP*) mutations 119
 transient receptor vanilloid 4 (*TRPV4*) mutations 226, 228
 traumatic brain injury (TBI)
 amyotrophic lateral sclerosis association 140
 Parkinson disease association 50
 Troyer syndrome 165
 tyros t-RNA synthetase (*YARS*) mutations 224
- ubiquilin-2 (*UBQLN2*) mutations 119, 141
 Unified Huntington's Disease Rating Scale (UHDRS) 267–268
- valosin-containing protein (*VCP*) mutations 119
 valproic acid (VPA) 193
 variably protease-sensitive prion disease (VPSPr) 25, 27
 pathology 28
 see also prion diseases
 variant CJD (vCJD) 25, 27, 28, 127
 diagnosis 128–129
 see also Creutzfeldt–Jakob disease (CJD)
 very long chain fatty acids (VLCFAs), X-linked adrenoleukodystrophy 309, 311, 313

- viral causes
 - amyotrophic lateral sclerosis 140
 - multiple sclerosis 239, 242
 - peripheral neuropathies 218
- Virchow–Robin space enlargement 5, 7, 242
- visual hallucinations, dementia with Lewy bodies 84
 - management 90
- visual loss, X-linked adrenoleukodystrophy 311
- vitamin D deficiency, multiple sclerosis and 239
- vorinostat 306
- voxel-based morphometry (VBM)
 - amyotrophic lateral sclerosis 147, 148
 - corticobasal degeneration 97, 97
- weight loss, Huntington's disease 253
- Werner syndrome 6
- Wilson disease 275, 324
- WNKI* mutations 229
- Wolfram syndrome 216
- Woodhouse–Sakati syndrome (WSS) 317, 322
- X-linked adrenoleukodystrophy (X-ALD) 309
 - biomarkers 311
 - clinical prodrome 311
 - diagnosis 313
 - endocrine evaluation 311
 - epidemiology 309
 - future developments 314
 - genetics 310–311
 - neuroimaging 312–313, 312
 - neurological examination 311
 - neuropathology 310
- neuropsychological testing 311–312
- pathophysiology 311
- prognosis 313
- spectrum of clinical phenotype
 - 309–310, **309**
 - asymptomatic boys and men 310
 - cerebral X-ALD 309
 - spinocerebellar variant 309–310
 - symptomatic female heterozygote 310
- treatment options 313–314
 - family-based and third-party care 314
 - gene therapy 314
 - medical treatment 313
 - stem cell therapy 313–314
- YARS mutations 224